<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00132613</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG9811</org_study_id>
    <secondary_id>C000000030</secondary_id>
    <nct_id>NCT00132613</nct_id>
  </id_info>
  <brief_title>Trial of Drainage With or Without Bleomycin Instillation for Malignant Pericardial Effusion</brief_title>
  <official_title>A Randomized Controlled Trial to Evaluate the Efficacy of Intra-pericardial Instillation of a Sclerosing Agent After Pericardial Drainage in Patients With Malignant Pericardial Effusion Associated With Lung Cancer (JCOG9811)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Japan Clinical Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of pericardial instillation of
      bleomycin as a sclerosing agent after pericardial drainage for lung cancer-associated
      malignant pericardial effusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malignant pericardial effusions (MPEs), which are commonly associated with cardiac tamponade,
      make oncologic emergencies requiring prompt drainage. In lung cancer patients, MPE is one of
      the most unpleasant terminal events. Drainage usually results in prompt palliation of
      symptoms, but recurrent effusions often occur. Sclerosis with pericardial instillation of
      various agents is reported to prevent the recurrence, and bleomycin is the most commonly used
      drug, with fewer toxicities compared with others. There is, however, no prospective trial of
      pericardial sclerosis as compared with drainage alone for MPEs, and it is far from clear
      whether sclerosis really benefits these patients in terminal stages.

      Comparison: Intra-pericardial instillation of bleomycin after pericardial drainage versus
      drainage alone for MPEs caused by lung cancer.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 1999</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without pericardial effusion at 2 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Successful extubation of pericardial drainage tube</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to extubation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>survival without pericardial effusion at 1, 2, 4, 6, 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>symptom palliation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>long-term (&gt; 6 months) effect on cardiac function</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Malignant Pericardial Effusion</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Procedure/Surgery: Observation alone after pericardial drainage</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Pericardial instillation of bleomycin after drainage</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Observation alone after pericardial drainage</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pericardial instillation of bleomycin after drainage</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically documented lung cancer

          -  Clinically stable condition after pericardial drainage for malignant pericardial
             effusion (not necessary that it be documented by cytology)

          -  Expected to live 6 weeks or longer

          -  Sufficient organ function

          -  Signed informed consent

        Exclusion Criteria:

          -  Myocardial infarction or unstable angina within 3 months

          -  Constrictive pericarditis

          -  Active pneumonitis

          -  Severe infection or disseminated intravascular coagulation (DIC)

          -  Other severe co-morbidity which could not be relieved with pericardial drainage

          -  Chemotherapy-naive small cell lung cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomohide Tamura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Center Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya,Chikusa-ku,Kanokoden,1-1</city>
        <state>Aichi</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center,Aichi Hospital</name>
      <address>
        <city>Okazaki,Kake-machi,Kuriyado,18</city>
        <state>Aichi</state>
        <zip>444-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa,Kashiwanoha,6-5-1</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Shikoku Cancer Center</name>
      <address>
        <city>Matsuyama,Horinouchi,13</city>
        <state>Ehime</state>
        <zip>790-0007</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka,Higashi-ku,Maidashi,3-1-1</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Municipal Hospital</name>
      <address>
        <city>Gifu,Kashima-cho,7-1</city>
        <state>Gifu</state>
        <zip>500-8323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gunma Prefectural Cancer Center</name>
      <address>
        <city>Ota,Takabayashi-nishi-cho,617-1</city>
        <state>Gunma</state>
        <zip>373-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Nishigunma Hospital</name>
      <address>
        <city>Shibukawa,Kanai,2854</city>
        <state>Gunma</state>
        <zip>377-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization, Dohoku National Hospital</name>
      <address>
        <city>Asahikawa,Hanasaki,7-4048</city>
        <state>Hokkaido</state>
        <zip>070-8644</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Hokkaido Cancer Center</name>
      <address>
        <city>Sapporo,Shiroishi-ku,Kikusui,4-2-3-54</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kobe City General Hospital</name>
      <address>
        <city>Kobe,Chuo-ku,Minatojimanakamachi,4-6</city>
        <state>Hyogo</state>
        <zip>650-0046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine</name>
      <address>
        <city>Nishinomiya,Mukogawa-cho,1-1</city>
        <state>Hyogo</state>
        <zip>663-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ibaraki Kenritsu Chuo Hospital &amp; Cancer Center</name>
      <address>
        <city>Nishi-ibarakigun,Tomobemachi,Koibuchi,6528</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama,Asahi-ku,Nakao,1-1-2</city>
        <state>Kanagawa</state>
        <zip>241-0815</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama Mucipical Citizen's Hospital</name>
      <address>
        <city>Yokohama,Hodogaya-ku,Okazawa-cho,56</city>
        <state>Kanagawa</state>
        <zip>240-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Regional Medical Center Hospital</name>
      <address>
        <city>Kumamoto,Honjo,5-16-10</city>
        <state>Kumamoto</state>
        <zip>860-0811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai,Aoba-ku,Seiryo-machi,1-1</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niigata Cancer Center Hospital</name>
      <address>
        <city>Niigata,Kawagishi-cho,2-15-3</city>
        <state>Niigata</state>
        <zip>951-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Prefectural Medical Center for Respiratory and Allergic Disease</name>
      <address>
        <city>Habikino,Habikino,3-7-1</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Izumisano,rinku-ohrai-kita,2-23</city>
        <state>Osaka</state>
        <zip>598-0048</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graduate School of Medicine, Osaka City University</name>
      <address>
        <city>Osaka,Abeno-ku,Asahi-machi,1-5-7</city>
        <state>Osaka</state>
        <zip>545-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center for Cancer and Cardiovascular Diseases</name>
      <address>
        <city>Osaka,Higashinari-ku,Nakamichi,1-3-3</city>
        <state>Osaka</state>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinki University School of Medicine</name>
      <address>
        <city>Osaka-Sayama,Ohno-higashi,377-2</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-Chuo Chest Medical Center</name>
      <address>
        <city>Sakai,Nagasone,1180</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama National Hospital</name>
      <address>
        <city>Toyonaka,Toneyama,5-1-1</city>
        <state>Osaka</state>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Cancer Center</name>
      <address>
        <city>Kita-adachi,Ina,Komuro,818</city>
        <state>Saitama</state>
        <zip>362-0806</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Cancer Center</name>
      <address>
        <city>Utsunomiya,Yohnan,4-9-13</city>
        <state>Tochigi</state>
        <zip>320-0834</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku,Tsukiji, 5-1-1</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital</name>
      <address>
        <city>Koto-ku,Ariake,3-10-6</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Medical Center of Japan</name>
      <address>
        <city>Shinjuku-ku,Toyama,1-21-1</city>
        <state>Tokyo</state>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamagata Prefectural Central Hospital</name>
      <address>
        <city>Yamagata,Aoyagi,1800</city>
        <state>Yamagata</state>
        <zip>990-2292</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2005</study_first_submitted>
  <study_first_submitted_qc>August 19, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <name_title>Tomohide Tamura , MD</name_title>
    <organization>Japan Clinical Oncology Group</organization>
  </responsible_party>
  <keyword>pulmonary neoplasm</keyword>
  <keyword>malignant pericardial effusion</keyword>
  <keyword>pericardial drainage</keyword>
  <keyword>randomized trial</keyword>
  <keyword>bleomycin</keyword>
  <keyword>intrapericardial instillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pericardial Effusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bleomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

